Effects of intravenously administered C-type natriuretic peptide in humans: Comparison with atrial natriuretic peptide

T. Igaki, Hiroshi Itoh, S. I. Suga, N. Hama, Y. Ogawa, Y. Komatsu, J. Yamashita, K. Doi, T. Chun, K. Nakao

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human atrial natriuretic peptide (hANP), we intravenously administered synthetic CNP (0.43 nmol/kg) and α-hANP (0.43 and 0.043 nmol/kg) to healthy humans. The experiments were done on different days in the same five healthy volunteers (31 ± 1 yr old). CNP injection caused a transient but significant decrease in both systolic and diastolic blood pressure (-4.3 ± 1.3, -4.1 ± 1.0 mmHg) with a significant increase in heart rate (+7.6 ± 2.6 bpm), and exerted significant diuretic and natriuretic activities (+130 ± 80%, +160 ± 100% over the basal level). These effects of CNP (0.43 nmol/kg) were comparable to, or less than, those of α-hANP (0.043 nmol/kg). CNP injection also significantly suppressed aldosterone secretion (22% reduction as compared with the basal level). Our results demonstrate that intravenously-administered CNP acts as a natriuretic peptide with less potency than ANP.

Original languageEnglish
Pages (from-to)7-13
Number of pages7
JournalHypertension Research - Clinical and Experimental
Volume21
Issue number1
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

C-Type Natriuretic Peptide
Atrial Natriuretic Factor
Natriuretic Peptides
Blood Pressure
Injections
Aldosterone
Diuretics
Blood Vessels
Healthy Volunteers
Endothelial Cells
Heart Rate

Keywords

  • Atrial natriuretic peptide (ANP)
  • Blood pressure
  • C-type natriuretic peptide (CNP)
  • Guanosine 3',5'-cyclic monophosphate (cGMP)
  • Natriuresis

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effects of intravenously administered C-type natriuretic peptide in humans : Comparison with atrial natriuretic peptide. / Igaki, T.; Itoh, Hiroshi; Suga, S. I.; Hama, N.; Ogawa, Y.; Komatsu, Y.; Yamashita, J.; Doi, K.; Chun, T.; Nakao, K.

In: Hypertension Research - Clinical and Experimental, Vol. 21, No. 1, 1998, p. 7-13.

Research output: Contribution to journalArticle

Igaki, T, Itoh, H, Suga, SI, Hama, N, Ogawa, Y, Komatsu, Y, Yamashita, J, Doi, K, Chun, T & Nakao, K 1998, 'Effects of intravenously administered C-type natriuretic peptide in humans: Comparison with atrial natriuretic peptide', Hypertension Research - Clinical and Experimental, vol. 21, no. 1, pp. 7-13.
Igaki, T. ; Itoh, Hiroshi ; Suga, S. I. ; Hama, N. ; Ogawa, Y. ; Komatsu, Y. ; Yamashita, J. ; Doi, K. ; Chun, T. ; Nakao, K. / Effects of intravenously administered C-type natriuretic peptide in humans : Comparison with atrial natriuretic peptide. In: Hypertension Research - Clinical and Experimental. 1998 ; Vol. 21, No. 1. pp. 7-13.
@article{11c974b724ed435d80d57eee097b5acc,
title = "Effects of intravenously administered C-type natriuretic peptide in humans: Comparison with atrial natriuretic peptide",
abstract = "We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human atrial natriuretic peptide (hANP), we intravenously administered synthetic CNP (0.43 nmol/kg) and α-hANP (0.43 and 0.043 nmol/kg) to healthy humans. The experiments were done on different days in the same five healthy volunteers (31 ± 1 yr old). CNP injection caused a transient but significant decrease in both systolic and diastolic blood pressure (-4.3 ± 1.3, -4.1 ± 1.0 mmHg) with a significant increase in heart rate (+7.6 ± 2.6 bpm), and exerted significant diuretic and natriuretic activities (+130 ± 80{\%}, +160 ± 100{\%} over the basal level). These effects of CNP (0.43 nmol/kg) were comparable to, or less than, those of α-hANP (0.043 nmol/kg). CNP injection also significantly suppressed aldosterone secretion (22{\%} reduction as compared with the basal level). Our results demonstrate that intravenously-administered CNP acts as a natriuretic peptide with less potency than ANP.",
keywords = "Atrial natriuretic peptide (ANP), Blood pressure, C-type natriuretic peptide (CNP), Guanosine 3',5'-cyclic monophosphate (cGMP), Natriuresis",
author = "T. Igaki and Hiroshi Itoh and Suga, {S. I.} and N. Hama and Y. Ogawa and Y. Komatsu and J. Yamashita and K. Doi and T. Chun and K. Nakao",
year = "1998",
language = "English",
volume = "21",
pages = "7--13",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Effects of intravenously administered C-type natriuretic peptide in humans

T2 - Comparison with atrial natriuretic peptide

AU - Igaki, T.

AU - Itoh, Hiroshi

AU - Suga, S. I.

AU - Hama, N.

AU - Ogawa, Y.

AU - Komatsu, Y.

AU - Yamashita, J.

AU - Doi, K.

AU - Chun, T.

AU - Nakao, K.

PY - 1998

Y1 - 1998

N2 - We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human atrial natriuretic peptide (hANP), we intravenously administered synthetic CNP (0.43 nmol/kg) and α-hANP (0.43 and 0.043 nmol/kg) to healthy humans. The experiments were done on different days in the same five healthy volunteers (31 ± 1 yr old). CNP injection caused a transient but significant decrease in both systolic and diastolic blood pressure (-4.3 ± 1.3, -4.1 ± 1.0 mmHg) with a significant increase in heart rate (+7.6 ± 2.6 bpm), and exerted significant diuretic and natriuretic activities (+130 ± 80%, +160 ± 100% over the basal level). These effects of CNP (0.43 nmol/kg) were comparable to, or less than, those of α-hANP (0.043 nmol/kg). CNP injection also significantly suppressed aldosterone secretion (22% reduction as compared with the basal level). Our results demonstrate that intravenously-administered CNP acts as a natriuretic peptide with less potency than ANP.

AB - We have previously reported that C-type natriuretic peptide (CNP), the third member of the natriuretic peptide family, is produced in vascular endothelial cells and suggested that CNP might be a local regulator of vascular tone and growth. To evaluate the biological actions of CNP as compared with human atrial natriuretic peptide (hANP), we intravenously administered synthetic CNP (0.43 nmol/kg) and α-hANP (0.43 and 0.043 nmol/kg) to healthy humans. The experiments were done on different days in the same five healthy volunteers (31 ± 1 yr old). CNP injection caused a transient but significant decrease in both systolic and diastolic blood pressure (-4.3 ± 1.3, -4.1 ± 1.0 mmHg) with a significant increase in heart rate (+7.6 ± 2.6 bpm), and exerted significant diuretic and natriuretic activities (+130 ± 80%, +160 ± 100% over the basal level). These effects of CNP (0.43 nmol/kg) were comparable to, or less than, those of α-hANP (0.043 nmol/kg). CNP injection also significantly suppressed aldosterone secretion (22% reduction as compared with the basal level). Our results demonstrate that intravenously-administered CNP acts as a natriuretic peptide with less potency than ANP.

KW - Atrial natriuretic peptide (ANP)

KW - Blood pressure

KW - C-type natriuretic peptide (CNP)

KW - Guanosine 3',5'-cyclic monophosphate (cGMP)

KW - Natriuresis

UR - http://www.scopus.com/inward/record.url?scp=0031957394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031957394&partnerID=8YFLogxK

M3 - Article

C2 - 9582102

AN - SCOPUS:0031957394

VL - 21

SP - 7

EP - 13

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 1

ER -